Do your Microsoft Excel spreadsheets pass FDA muster? Can they meet strict 21 CFR Part 11 standards? Would you like to learn a defined approach that can make your task simple and straightforward saving you both time and money? Order this hands-on learning experience led by a trusted spreadsheet validation expert. Training is critical for anyone in the drug or device industry who oversees or uses spreadsheets for data collection, data processing or data reporting.
It's every drug- and devicemaker’s worst nightmare — inspectors coming through your front door with the power to shut you down. They're highly trained … ruthlessly committed to spotting your tiniest flaws … and tough as nails. If only you could question investigators in detail … before an inspection. Maybe you'd learn what you need to do to pass. Would they tell you? The answer is yes.
Eli Lilly’s Alzheimer’s disease candidate solanezumab may offer potential as a treatment for milder forms of the disease, new detailed data reveal, but the company’s prospects are still flimsy, with odds of failure potentially exceeding more than 50 percent, one analyst says. The drug reduced cognitive decline by 34 percent in a secondary analysis of pooled data from mild Alzheimer’s patients in the two pivotal studies, a statistically significant result, Lilly said. Drug Industry Daily